Ontology highlight
ABSTRACT:
SUBMITTER: Tu MM
PROVIDER: S-EPMC6382401 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature
Science advances 20190220 2
While a fraction of cancer patients treated with anti-PD-1 show durable therapeutic responses, most remain unresponsive, highlighting the need to better understand and improve these therapies. Using an in vivo screening approach with a customized shRNA pooled library, we identified DDR2 as a leading target for the enhancement of response to anti-PD-1 immunotherapy. Using isogenic in vivo murine models across five different tumor histologies-bladder, breast, colon, sarcoma, and melanoma-we show t ...[more]